Avior Wealth Management’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-131
Closed -$12.4K 2460
2024
Q1
$12.4K Buy
+131
New +$11.2K ﹤0.01% 1788
2023
Q1
Sell
-4,040
Closed -$177K 1635
2022
Q4
$177K Hold
4,040
0.01% 481
2022
Q3
$266K Sell
4,040
-3,115
-44% -$200K 0.02% 403
2022
Q2
$361K Hold
7,155
0.04% 318
2022
Q1
$457K Sell
7,155
-394
-5% -$28.3K 0.04% 310
2021
Q4
$808K Sell
7,549
-288
-4% -$30.1K 0.07% 234
2021
Q3
$805K Hold
7,837
0.07% 224
2021
Q2
$689K Sell
7,837
-34
-0.4% -$3.12K 0.07% 234
2021
Q1
$765K Buy
7,871
+3,125
+66% +$312K 0.08% 214
2020
Q4
$532K Sell
4,746
-1,504
-24% -$158K 0.07% 251
2020
Q3
$579K Buy
6,250
+390
+7% +$30K 0.08% 207
2020
Q2
$457K Buy
5,860
+720
+14% +$48.7K 0.07% 248
2020
Q1
$300K Buy
5,140
+1,400
+37% +$90.1K 0.06% 272
2019
Q4
$299K Sell
3,740
-850
-19% -$63.6K 0.05% 325
2019
Q3
$337K Buy
4,590
+1,880
+69% +$163K 0.06% 275
2019
Q2
$256K Buy
2,710
+780
+40% +$64.4K 0.05% 325
2019
Q1
$154K Sell
1,930
-70
-4% -$5.17K 0.03% 367
2018
Q4
$107K Buy
2,000
+390
+24% +$23.7K 0.03% 424
2018
Q3
$126K Buy
+1,610
New +$112K 0.03% 420

Other funds holding BPMC

Avior Wealth Management's BPMC Position: Q2 2024 in Review

Avior Wealth Management sold out of Blueprint Medicines (BPMC) in Q2 2024, closing a stake of 131 shares — an estimated $12.4K sold.

Avior Wealth Management first reported a position in BPMC in Q3 2018 and held it in 19 quarters. The position peaked at $808K in Q4 2021. 305 funds tracked by Wall St. Rank hold BPMC as of Q2 2024.

  • Avior Wealth Management reported no remaining Blueprint Medicines position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 131 Blueprint Medicines shares in Q2 2024, an estimated $12.4K.
  • Avior Wealth Management first reported a position in Blueprint Medicines in Q3 2018 and held it in 19 quarters.
  • Avior Wealth Management's Blueprint Medicines position peaked at $808K in Q4 2021.
  • 305 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.